Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026
Business Wire•28/10/2026•16:05 ET
0
Key Highlights
- ➤Acadia (ACAD) to participate in UBS Global Biopharma Conference fireside chat November 17, 2026
- ➤Live webcast and archived recording will be available on Acadia’s investor website
- ➤Commercial portfolio includes FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome
- ➤Pipeline includes mid- to late-stage programs in Alzheimer’s and Lewy body dementia psychosis
Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the UBS Global Biopharma Conference 2026 on Tuesday, November 17, 2026 at 12:40 p.m. Greenwich Mean Time.
Get started
Create a free account to read the full story.